The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.
about
Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer TreatmentRaf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cellsTheranostic imaging of cancer.Correlation between PDZK1, Cdc37, Akt and breast cancer malignancy: the role of PDZK1 in cell growth through Akt stabilization by increasing and interacting with Cdc37Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceProfiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.Risk factors for distant metastasis as a primary site of treatment failure in early-stage breast cancer.Cancer stem cells and side population cells in breast cancer and metastasis.GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor.Comparing the Effect of Silybin and Silybin Advanced™ on Viability and HER2 Expression on the Human Breast Cancer SKBR3 Cell Line by no Serum Starvation.YB-1 drives preneoplastic progression: Insight into opportunities for cancer preventionRelationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancerT cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumorsSuppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatmentOncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perilsGastric obstruction secondary to metastatic breast cancer: a case report and literature reviewWASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signalingA Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis.Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development.Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.Stem cells of the breast and cancer therapy.c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC).Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.Isolation and characterization of adult mammary stem cells from breast cancer-adjacent tissues.Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathwayPredictors of cervical lymph node metastasis in salivary gland cancer.Decorated Superparamagnetic Iron Oxide Nanoparticles with Monoclonal Antibody and Diethylene-Triamine-Pentaacetic Acid Labeled with Thechnetium-99m and Galium-68 for Breast Cancer Imaging.Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.
P2860
Q27024816-7D837B72-BE50-4BDF-8C01-E5E8E4F1A768Q33759701-64B07216-FF27-4788-BB56-35104987FA23Q33791349-E584F864-E902-4093-B739-8197D12A1BA1Q33934600-A86DBDA3-A085-4995-BEEE-BC223334A586Q34084756-0202476F-AD8F-4F68-A27B-DBDC150EF14CQ34270803-91666881-F5B9-4122-9EB7-E243EA1AABCBQ34355748-86B1BF05-D003-4EDC-8E89-3C905CD94C4CQ34572719-67ABBE8D-7CC8-49E3-BFF7-E078283E8948Q34774308-D390423F-14BB-4355-8515-34D8A1DA5C43Q35038054-7E5D834A-B833-402D-B158-1E57044B5D90Q35051560-4762598E-1997-455C-A81D-3C4C4250ECC9Q35484007-40AE0935-FDBB-461E-902B-39970C0B1AD4Q35640233-4DE25C8B-C4A4-475D-A771-5FCB8A76F943Q35854297-7DFBC3B5-ACA0-4E55-91D8-F7B7D7AF9109Q35949083-E3AD0EEA-767A-426D-A8AF-E5E3E6040207Q35979751-8F92EF9B-CF32-49EF-93FC-7CF66BBE426CQ36038823-25AB341B-9C57-455C-9A24-B94A13042177Q36175779-138B03C1-A0F2-493B-89CA-3401BAE167E0Q37124053-067F46B3-0C39-4B93-9DAE-1DD115978845Q37414060-64B32E88-94F8-4515-B629-3529D7B9349FQ37467189-8ED9F6EF-A81D-4067-92C4-09484A51EE9CQ37566023-65982A94-8B15-457F-B0A9-C0EE1E0E29FDQ37641777-293C1CCF-7FF7-4DBA-B35E-D859B69EDC03Q37699356-7DCE905D-F50E-49B1-8CA9-9B0E9871F735Q37833424-F3CA7C33-19D0-4214-ACD4-4A76493FC3B7Q38673589-FB814A0A-4B27-4CA2-8459-4736FF9840D5Q38849205-FA36E1A4-AAA7-4C22-A59A-761FB41C30E6Q39300010-F1BA681E-0CD5-4DF1-8053-0F48A1F15630Q39314472-422F1158-94BF-4978-A016-23237E29B77DQ41613134-D9B0A405-809B-47F5-BE15-0A8D4B171E77Q41694168-EDB604CC-374F-46B9-85D6-458CC350A637Q43529428-D7AAE005-E5C5-49C2-AD95-6B371478455CQ47197599-A94A62BB-C670-4D30-93C6-D2EBD71A38D2Q49378999-6B797F50-915A-4DA1-A5C2-51FFA68A8654Q51371303-3625388F-0A87-42DB-A360-4B47E5DD6121
P2860
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of HER2 in early brea ...... ce to HER2-targeted therapies.
@en
The role of HER2 in early brea ...... ce to HER2-targeted therapies.
@nl
type
label
The role of HER2 in early brea ...... ce to HER2-targeted therapies.
@en
The role of HER2 in early brea ...... ce to HER2-targeted therapies.
@nl
prefLabel
The role of HER2 in early brea ...... ce to HER2-targeted therapies.
@en
The role of HER2 in early brea ...... ce to HER2-targeted therapies.
@nl
P2093
P2860
P1476
The role of HER2 in early brea ...... ce to HER2-targeted therapies.
@en
P2093
Izumi Nagatomo
Jaclyn A Freudenberg
Jeffrey Drebin
Makoto Katsumata
Mark I Greene
P2860
P356
10.1016/J.YEXMP.2009.05.001
P577
2009-05-18T00:00:00Z